The synthetic ligand of peroxisome proliferator-activated receptor-γ ciglitazone affects human glioblastoma cell lines

Journal of Pharmacology and Experimental Therapeutics

Volumn 309, Issue 3, 2004, Pages 1239-1247

  Strakova, Nicol ^a   Ehrmann, Jiri ^a   Dzubak, Petr ^a   Bouchal, Jan ^a   Kolar, Zdenek ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CIGLITAZONE; CYCLIN B; CYCLIN D1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; RETINOBLASTOMA PROTEIN; TELOMERASE;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; NICK END LABELING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ADULT; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELL SURVIVAL; GENE EXPRESSION; GLIOBLASTOMA; HUMANS; HYPOGLYCEMIC AGENTS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 2442657794     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.063438     Document Type: Article

References (40)

1. Alleyne Ch, He J, Yang J, Hunter SB, Cotsonis G, James CD, and Olson JJ (1999) Analysis of cyclin dependent kinase inhibitors in malignant astrocytomas. Int J Oncol 14:1111-1116.
2. Bull AW (2003) The role of peroxisome proliferator-activated receptor y in colon cancer and inflammatory bowel disease. Arch Pathol Lab Med 127:1121-1123.
3. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, and Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47:936-942.
4. Chattopadhyay N, Singh DP, Heese O, Godbole MM, Sinohara T, Black PM, and Brown EM (2000) Expression of peroxisome proliferator-activated receptors (PPARs) in human astrocytic cells: PPARγ agonists as inducers of apoptosis. J Neurosci Res 61:67-74.
5. Cimini A, Cristiano L, Bernardo A, Farioli-Vecchioli S, Stefanini S, and Ceru MP (2000) Presence and inducibility of peroxisomes in human glioblastoma cell line. Biochim Biophys Acta 1474:397-409.
6. Ehrmann J, Vavrusova N, Collan Y, and Kolar Z (2002) PPARs in health and disease. Biomed Papers 146:11-14.
7. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, and Shintaku P (1998) Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95:8806-8811.
8. Everett L, Galli A, and Crabb D (2000) The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease. Liver 20:191-199.
9. Fan X, Aalto Y, Sanko SG, Knuutila S, Klatzmann D, and Castresana JS (2002) Genetic profile, PTEN mutation and therapeutic role of PTEN in glioblastomas. Int J Oncol 21:1141-1150.
10. Kip1 expression by contact inhibition as a prognostic index of human glioma. J Neurochem 74:1393-1399.
11. Guan YF, Zhang YH, Breyer RM, Davis L, and Breyer MD (1999) Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1:330-339.
12. Gurney JG and Kadan-Lottick N (2001) Brain and other central nervous system tumors: rates, trends and epidemiology. Curr Opin Oncol 13:160-166.
13. Waf1/Cip1 pathway. Hepatology 38:167-177.
14. Heuvel JP (1999) Peroxisome proliferator-activated receptors: a critical link among fatty acids, gene expression and carcinogenesis. J Nutr 129:575-580.
15. Hisatake JI, Ikezoe T, Holden S, Tomayasu S, and Koeffier PH (2000) Downregulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor γ in human. Cancer Res 60:5494-5498.
16. Houseknecht KL, Cole BM, and Steele PJ (2002) PPAR γ and its ligands: a review. Domest Anim Endocrinol 22:1-23.
17. Inoue K, Kawahito Y, Tsubouchi Y, Kohno M, Yoshimura R, Yoshikawa T, and Sano H (2001) Expression of peroxisome proliferator-activated receptor γ in renal cell carcinoma and growth inhibition by its agonists. Biochem Biophys Res Commun 287:727-732.
18. ARF, PTEN tumor suppressor genes in human glioblastoma cell lines. Brain Pathol 9:469-479.
19. James SY, Lin F, Kolluri SK, Dawson MI, and Zhang XK (2003) Regulation of retinoic acid receptor beta expression by peroxisome proliferator-activated receptor gamma ligands in cancer cells. Cancer Res 63:3531-3538.
20. Jiang H, Conrad C, Fueyo J, Gomez-Manzano C, and Liu TJ (2003) Oncolytic adenoviruses for malignant glioma therapy. Front Biosci 8:577-588.
21. Kato M, Nagaya T, Fujieda M, Saito K, Yoshida J, and Seo H (2002) Expression of PPARγ and its ligand-dependent growth inhibition in human brain tumor cell lines. Jpn J Cancer Res 93:660-666.
22. Kersten S, Desvergne B, and Wahli W (2000) Roles of PPARs in health and disease. Nature (Lond) 405:421-424.
23. Kim EJ, Park KS, Jung SY, Sheen YY, Moon DC, Song YS, Kim KS, Song S, Yun YP, Lee MK, et al. (2003) Peroxisome proliferator-activated receptor-gamma activator 15-deoxy-(delta)12,14-prostaglandin J2 inhibits neuroblastoma cell growth through induction of apoptosis: association with ERK signal pathway. J Pharmacol Exp Ther 307:505-517.
24. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, and Koeffier HP (1998) Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 58:3344-3352.
25. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, and Chambon P (1995) The nuclear receptor superfamily: the second decade. Cell 83:835-839.
26. Miller RT, Anderson SP, Corton JC, and Cattley RC (2000) Apoptosis, mitosis and cyclophilin-40 expression in regressing peroxisome proliferator-induced adenomas. Carcinogenesis 21:647-652.
27. Mohri M, Nitta H, and Yamashita J (2000) Expression of multidrug resistance-associated protein (MRP) in human gliomas. J Neurooncol 49:105-115.
28. Mischel PS and Cloughesy TF (2003) Targeted molecular therapy of GBM. Brain Pathol 13:52-61.
29. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, and Spiegelman BM (1998) Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1:465-470.
30. Murphy GJ and Holder JC (2000) PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 21:469-474.
31. Ohta K, Endo T, Haraguchi K, Hershman JM, and Onaya T (2001) Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 88:2170-2177.
32. Peters JM, Rusyn I, Rose ML, Gonzales FJ, and Thurman RG (2000) Peroxisome proliferator activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis. Carcinogenesis 21:823-826.
33. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, et al. (1998) Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4:1046-1052.
34. Takahashi N, Okumura T, Motomura W, Fujimoto Y, Kawabata I, and Kohgo Y (1999) Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 455:135-139.
35. Takashima T, Fujiwara Y, Higuchi K, Arakawa T, Yano Y, Hasuma T, and Otani S (2001) PPAR-gamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity. Int J Oncol 19:465-471.
36. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, Brun RP, Mueller E, Altiok S, Oppenheim H, et al. (1997) Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA 94:237-241.
37. Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, Inoue K, Hla T, and Kondo M (2000) Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun 270:400-405.
38. Waf1/Cip1 by modulating the protein kinase C delta pathway in vascular smooth muscle cells. J Biol Chem 276:47650-47657.
39. Wang C, Pattabiraman N, Zhou JN, Fu M, Sakamaki T, Albanese C, Li Z, Wu K, Hulit J, Neumeister P, et al. (2003) Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol Cell Biol 23: 6159-6173.
40. Yang WL and Frucht H (2001) Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 22:1379-1383.